Mark Bachleda
CIK 1887762 · Chief Commercial Officer · last filed 2025-06-11
Mark Bachleda is a Chief Commercial Officer who has filed 5 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for LYEL, was dated Jun 11, 2025. Across all open-market trades the lifetime net is +$24.7K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
5
$24.7K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LYEL | Director | — | $13.50 | — | $0 | 1 | 2025-06-11 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Chief Commercial Officer | 11,000 | $0.14 | $1.6K | $24.7K | 4 | 2023-03-20 |
Recent Filings
5 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-11 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2023-03-20 | Galera Therapeutics, Inc. (GRTX) Delisted | Buy (P) | +11,000 | $24.7K | EDGAR |
| 2023-02-28 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-02 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-10-12 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |